24 Sep CAR T Therapy: What Recent Research Is Showing
CAR T therapy has been around for a while now, but the research has not slowed down. What started as a last-resort option for a narrow group of blood cancer patients has grown into something researchers are now testing in earlier treatment stages, in new cancer types, and in combination with other therapies. Here is a look at where things stand.
For years, CAR-T therapy was mostly reserved for patients who had already tried everything else and seen it fail. That is shifting. Recent phase 3 clinical trials — including ZUMA-7 and TRANSFORM — showed significant improvements in event-free survival when CAR T-cell therapy was used earlier as a second-line treatment rather than waiting until multiple prior therapies had failed. According to the NCI (National Cancer Institute), CAR T-cell therapies work by engineering a patient's own T-cells to recognize and attack cancer cells, and the FDA has now approved multiple CAR T products for several blood cancers — with clinical research continuing to expand both the indications and the timing of their use.
[caption id="attachment_76221" align="aligncenter" width="500"] Pixabay[/caption]